GlassScriptPhysician profile
Karen C Lee
NPI 1780766857
$2,027.30
in general payments reported to CMS, 2019-2025
31 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $865 · 2020: $163 · 2021: $350 · 2022: $82.29 · 2023: $247 · 2024: $169 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $566.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $257.42 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $204.33 | 2019-2021 | |
| Amgen INC. | $186.87 | 2019-2023 | Prolia, Evenity |
| Scilex Pharmaceuticals INC. | $173.28 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $139.63 | 2021-2025 | Farxiga, Lokelma |
| Teva Pharmaceuticals USA, INC. | $137.60 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $125.57 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $121.89 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $71.83 | 2019-2024 | |
| Pfizer INC. | $71.42 | 2020-2021 | |
| Lilly USA, LLC | $60.44 | 2021-2023 | Mounjaro |
| Lundbeck LLC | $46.49 | 2023-2024 | Rexulti |
| Grifols USA, LLC | $43.24 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $40.36 | 2019-2022 | |
| Exact Sciences Corporation | $36.77 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $30.40 | 2021-2024 | |
| Glaxosmithkline, LLC. | $29.99 | 2019 | |
| Biogen, INC. | $29.79 | 2021 | |
| Eisai INC. | $28.11 | 2021-2023 | |
| Jazz Pharmaceuticals INC. | $23.57 | 2019 | |
| Boston Scientific Corporation | $21.51 | 2025 | Watchman Access System |
| Xeris Pharmaceuticals, INC. | $20.52 | 2023 | Gvoke Hypopen |
| Idorsia Pharmaceuticals US INC | $16.79 | 2023 | Quviviq |
| Aimmune Therapeutics, INC. | $16.63 | 2024 | |
| Abbott Laboratories | $14.88 | 2024 | Eterna |
| Insmed, INC. | $14.06 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $13.56 | 2025 | Rexulti |
| Collegium Pharmaceutical, INC. | $13.53 | 2025 | Belbuca |
| Ferring Pharmaceuticals INC. | $13.29 | 2023 | Rebyota |
| Cmp Pharma, INC. | $12.28 | 2022 | |
| Arbor Pharmaceuticals, INC. | $11.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.